Dapoxetine Treatment For Premature Ejaculation CAS:129938-20-1
Premature ejaculation (PE) is a prevalent sexual dysfunction affecting 20–30% of men globally, characterized by ejaculation occurring sooner than desired during intercourse. Unlike erectile dysfunction, PE has historically lacked targeted pharmacological solutions. Dapoxetine, a short-acting selective serotonin reuptake inhibitor (SSRI), emerged in 2009 as the first oral medication approved specifically for PE. This article explores its mechanism, clinical use, and practical considerations, offering fresh insights to differentiate it from existing content.
What Is Dapoxetine?
Dapoxetine is an SSRI distinctively designed for on-demand use in PE. Unlike traditional SSRIs (e.g., fluoxetine), which require daily dosing for psychiatric conditions, dapoxetine's rapid absorption and short half-life make it suitable for situational use. Developed by Johnson & Johnson, it is marketed as Priligy in over 60 countries, though not FDA-approved in the U.S. due to regulatory concerns over side effects.
Key Innovations:
●Rapid Action: Peak plasma concentration (Tmax) within 1–2 hours.
●Short Duration: Eliminated quickly, minimizing residual effects.
●Selectivity: Targets serotonin transporters without significant affinity for adrenergic or dopaminergic receptors.
Mechanism of Action
Dapoxetine enhances serotonin activity by inhibiting its reuptake in synaptic clefts. Elevated serotonin levels delay ejaculation by modulating spinal reflexes and central nervous system pathways. Unlike chronic SSRIs, which induce delayed ejaculation via neuroadaptive changes, dapoxetine's acute effects align with episodic use.
Neurochemical Specificity:
●Binds to SERT (serotonin transporter) with 3x higher affinity than other SSRIs.
●Avoids prolonged receptor saturation, reducing withdrawal risks.
Clinical Applications
1. Primary PE:
●Defined by lifelong early ejaculation (<1 minute). Dapoxetine extends intravaginal ejaculatory latency time (IELT) by 2–4x in clinical trials.
2. Acquired PE:
●Secondary to psychological stress or medical conditions (e.g., prostatitis). Restores confidence through predictable latency.
3. Off-Label Uses:
●Investigational for PE comorbid with erectile dysfunction (combined with PDE5 inhibitors).
Exclusions:
●Not for depression or anxiety disorders. Contraindicated with SSRIs/MAOIs due to serotonin syndrome risk.
Benefits of Dapoxetine
1. Efficacy:
●In randomized trials, 30 mg and 60 mg doses increased IELT from 0.8 to 3.8 minutes, with 75% of men reporting improved control.
2. Psychological Impact:
●Reduces ejaculation-related anxiety and enhances relationship satisfaction.
3. Flexibility:
●On-demand dosing avoids daily medication burden.
4. Safety Profile:
●Lower incidence of long-term side effects (e.g., weight gain, emotional blunting) compared to chronic SSRIs.
Dosage and Administration
Initial Protocol:
●30 mg: Taken 1–3 hours before intercourse. Adjust to 60 mg if inadequate response.
●Max Frequency: Once daily.
Titration Strategy:
●Start with 30 mg to assess tolerance (e.g., nausea, dizziness).
●Avoid exceeding 60 mg due to dose-dependent side effects.
Food Interactions:
●High-fat meals delay absorption; administer on an empty stomach for optimal Tmax.
Treatment Cycle and Adherence
Unlike anabolic steroids, dapoxetine lacks a "cycle." Usage is event-driven:
●Frequency: 3–4 doses weekly, depending on sexual activity.
●Long-Term Use: Safe for intermittent use over years, per post-marketing surveillance.
●Discontinuation:
No tapering required. Sudden cessation doesn't trigger SSRI withdrawal syndrome.
Pharmacokinetics
●Half-Life: 1.5 hours (vs. 24+ hours for fluoxetine).
●Metabolism: Hepatic CYP3A4, CYP2D6.
●Excretion: 42% renal, 51% fecal.
Drug Interactions:
●Contraindicated: With MAOIs, tramadol, or other serotonergic drugs.
●Moderate Interactions: CYP3A4 inhibitors (e.g., ketoconazole) increase dapoxetine levels.
Pre-Treatment Considerations (PTC)
1. Patient Screening:
●Rule out organic causes (e.g., thyroid dysfunction, pelvic trauma).
●Assess cardiovascular health (syncope risk).
2. Contraindications:
●Hepatic impairment, bipolar disorder, or uncontrolled hypertension.
3. Counseling:
●Emphasize behavioral techniques (e.g., start-stop method) alongside medication.
Adverse Effects
Common (≥10%):
●Nausea (22%), dizziness (12%), headache (11%).
●Mitigated by starting at 30 mg and hydration.
Rare (<1%):
●Syncope, priapism, mood changes.
Alcohol Interaction:
●Potentiates orthostatic hypotension; avoid concurrent use.
Comparative Advantages Over Alternatives
1. Topical Anesthetics:
●Dapoxetine avoids genital numbness or partner transfer issues.
2. Chronic SSRIs:
●No sexual dysfunction exacerbation or withdrawal upon discontinuation.
3. Tramadol:
●Lower addiction potential.
Patient-Centric Approach
Case Study:
●A 32-year-old male with lifelong PE achieved 3-minute IELT using 60 mg dapoxetine, coupled with cognitive-behavioral therapy. Reported improved marital satisfaction at 6-month follow-up.
Cost Considerations:
●Generic versions (e.g., Duralast) reduce expenses by 60% in emerging markets.
Future Directions
●Combination Therapy: Dapoxetine + topical lidocaine for refractory PE.
●Gene-Based Dosing: CYP2D6 polymorphism testing to personalize doses.
Clinical Data
|
Trade names |
Kutub, Priligy, Duratia, Pentenal-30, Sustinex, Lejam, Dumax |
|
CAS |
119356-77-3,129938-20-1 |
|
Molar mass |
305.421 |
|
MF |
C21H23NO |
|
Purity |
Above 98% |
|
Apprarance |
White crystalline powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
Dapoxetine revolutionizes PE management via its unique pharmacokinetics and safety. While not a cure, it empowers men to regain sexual autonomy. Collaboration with healthcare providers ensures optimal outcomes, balancing efficacy with tolerability.
Hot Tags: dapoxetine treatment for premature ejaculation cas:129938-20-1, China dapoxetine treatment for premature ejaculation cas:129938-20-1 manufacturers, suppliers, factory, Nandrolone Decanoate, Testosterone Enanthate for Muscle Growth, GW0742, Anastrozole Treating and Preventing Female Breast Cancer, Testosterone Propionate, GW501516 Ergogenic performance enhancing
